Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

This study has been terminated.
(Based on futility analysis showing <30% chance of meeting primary endpoint.)
Information provided by:
Cell Genesys Identifier:
First received: August 16, 2004
Last updated: November 3, 2008
Last verified: November 2008
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2008
  Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):